Report #2825496

Received Feb 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 88 yrs
State: OR
Recovered: Unknown
Vaccinated: Jan 24, 2025
Onset: Jan 24, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

patient received her second dose of Shingrix 15 days after the first; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 88-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included VARICELLA ZOSTER VACCINE RGE (CHO) (SHINGRIX). On 24-JAN-2025, the patient received the 2nd dose of Shingrix. On 24-JAN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: patient received her second dose of Shingrix 15 days after the first). The outcome of the drug dose administration interval too short was unknown. Additional Information: GSK Receipt Date : 04-FEB-2025 Pharmacist stated that a patient received her second dose of Shingrix 15 days after the first (earlier than the recommended interval), which led to shortening of vaccine schedule.